• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宫颈原位癌年龄依赖性消退的流行病学证据。

Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer.

作者信息

van Oortmarssen G J, Habbema J D

机构信息

Department of Public Health and Social Medicine, Medical Faculty, Erasmus University, Rotterdam, The Netherlands.

出版信息

Br J Cancer. 1991 Sep;64(3):559-65. doi: 10.1038/bjc.1991.350.

DOI:10.1038/bjc.1991.350
PMID:1911199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1977665/
Abstract

Data from the screening programme in British Columbia are used to test hypotheses about the natural history of cervical cancer, especially about progression and regression of preclinical lesions (dysplasia and carcinoma in situ). Three models are considered. A model without regression does not give an adequate fit of the data (P less than 0.001), and results in an implausible estimate of 33 years for the mean duration of pre-invasive lesions. A model with an equal regression rate at all ages still does not result in a good reproduction of the data. A good fit is achieved for a model with different regression rates in lesions that develop under and over age 34. Under age 34, 84% of the new lesions will regress spontaneously, with a 95% confidence interval of 76-92% regression. Over age 34, we estimate that 40% of the new lesions will regress. The average duration of dysplasia + CIS is 11.8 years, and the sensitivity of the Pap-smear is 80%. It is concluded that a considerable proportion of pre-invasive lesions in young women do not progress. The findings about progression and duration of pre-invasive lesions do not support the still prevailing tendency of frequently making Pap smears in young women.

摘要

来自不列颠哥伦比亚省筛查项目的数据被用于检验关于宫颈癌自然史的假设,尤其是关于临床前病变(发育异常和原位癌)的进展和消退情况。考虑了三种模型。一种无消退的模型不能很好地拟合数据(P小于0.001),并得出侵袭前病变平均持续时间为33年的不合理估计。一种所有年龄回归率相同的模型仍然不能很好地再现数据。对于34岁以下和34岁以上发生的病变具有不同回归率的模型,能实现良好的拟合。34岁以下,84%的新病变会自发消退,95%置信区间的消退率为76 - 92%。34岁以上,估计40%的新病变会消退。发育异常 + 原位癌的平均持续时间为11.8年,巴氏涂片的敏感性为80%。得出的结论是,年轻女性中相当一部分侵袭前病变不会进展。关于侵袭前病变进展和持续时间的研究结果不支持目前仍然普遍存在的在年轻女性中频繁进行巴氏涂片检查的倾向。

相似文献

1
Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer.宫颈原位癌年龄依赖性消退的流行病学证据。
Br J Cancer. 1991 Sep;64(3):559-65. doi: 10.1038/bjc.1991.350.
2
Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears.
Int J Epidemiol. 1995 Apr;24(2):300-7. doi: 10.1093/ije/24.2.300.
3
Cervical cancer incidence in British Columbia: Predicting effects of changes from Pap to human papillomavirus screening and of changes in screening participation.不列颠哥伦比亚省的宫颈癌发病率:预测从巴氏涂片筛查转变为人乳头瘤病毒筛查以及筛查参与率变化所产生的影响。
J Med Screen. 2017 Dec;24(4):195-200. doi: 10.1177/0969141316673673. Epub 2016 Nov 3.
4
The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer.挪威1992 - 2000年宫颈癌筛查项目:巴氏涂片覆盖率及宫颈癌发病率的变化
J Med Screen. 2002;9(2):86-91. doi: 10.1136/jms.9.2.86.
5
Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives.巴氏涂片检查后浸润性宫颈癌的风险:多次阴性结果的保护作用。
J Med Screen. 2005;12(1):7-11. doi: 10.1258/0969141053279103.
6
Risk of invasive cervical cancer after three consecutive negative Pap smears.连续三次巴氏涂片检查结果均为阴性后发生浸润性宫颈癌的风险。
J Med Screen. 2003;10(4):196-200. doi: 10.1258/096914103771773302.
7
Natural history of dysplasia of the uterine cervix.子宫颈发育异常的自然病史。
J Natl Cancer Inst. 1999 Feb 3;91(3):252-8. doi: 10.1093/jnci/91.3.252.
8
Detection of preinvasive cancer of the cervix and the subsequent reduction in invasive cancer.子宫颈癌前病变的检测及随后浸润性癌的减少。
J Natl Cancer Inst. 1993 Jul 7;85(13):1050-7. doi: 10.1093/jnci/85.13.1050.
9
History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.中国最大的妇女医院的经验:一大群浸润性宫颈癌患者的高危人乳头瘤病毒感染史和巴氏试验结果
Cancer Cytopathol. 2015 Jul;123(7):421-7. doi: 10.1002/cncy.21545. Epub 2015 May 8.
10
A mobile unit: an effective service for cervical cancer screening among rural Thai women.一个移动单元:泰国农村妇女宫颈癌筛查的有效服务。
Int J Epidemiol. 1999 Feb;28(1):35-9. doi: 10.1093/ije/28.1.35.

引用本文的文献

1
The Predictive Impact of HPV Genotypes, Tumor Suppressors and Local Immune Response in the Regression of Cervical Intraepithelial Neoplasia 2-3: A Prospective Population-Based Cohort Study.人乳头瘤病毒基因型、肿瘤抑制因子和局部免疫反应对宫颈上皮内瘤变2-3级消退的预测影响:一项基于人群的前瞻性队列研究。
Int J Mol Sci. 2025 May 28;26(11):5205. doi: 10.3390/ijms26115205.
2
Human malignancies associated with persistent HPV infection.人恶性肿瘤与持续性 HPV 感染相关。
Oncologist. 2024 Jun 3;29(6):457-464. doi: 10.1093/oncolo/oyae071.
3
A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival.一种识别CIN3消退和宫颈癌生存情况的基因特征。
Cancers (Basel). 2021 Nov 16;13(22):5737. doi: 10.3390/cancers13225737.
4
Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial.预防性四价 HPV 疫苗可否用于 CIN 妇女的治疗?一项随机试验。
BMC Public Health. 2020 Feb 27;20(1):274. doi: 10.1186/s12889-020-8371-z.
5
Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis.使用仿真模型估计宫颈癌的自然史:CISNET 比较分析。
J Natl Cancer Inst. 2020 Sep 1;112(9):955-963. doi: 10.1093/jnci/djz227.
6
16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot.16/18 基因分型在英国宫颈筛查试验中细胞学阴性的持续性人乳头瘤病毒感染中的分流作用。
Br J Cancer. 2019 Sep;121(6):455-463. doi: 10.1038/s41416-019-0547-x. Epub 2019 Aug 14.
7
Follow-Up of Women with Cervical Cytological Abnormalities: Progression and Regression Events.宫颈细胞学异常女性的随访:进展和消退事件
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1019-1024. doi: 10.31557/APJCP.2019.20.4.1019.
8
Danish method study on cervical screening in women offered HPV vaccination as girls (Trial23): a study protocol.针对女童接种人乳头瘤病毒疫苗的女性进行子宫颈癌筛查的丹麦方法研究(试验23):研究方案
BMJ Open. 2018 May 26;8(5):e020294. doi: 10.1136/bmjopen-2017-020294.
9
Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis.主动监测下未经治疗的2级宫颈上皮内瘤变的临床病程:系统评价和荟萃分析
BMJ. 2018 Feb 27;360:k499. doi: 10.1136/bmj.k499.
10
Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia.用于评估睡茄内酯A的山羊模型的建立:用于治疗宫颈上皮内瘤变的宫颈植入物。
Exp Mol Pathol. 2017 Dec;103(3):320-329. doi: 10.1016/j.yexmp.2017.11.008. Epub 2017 Nov 21.

本文引用的文献

1
[The development and treatment of epitheliomas].[上皮瘤的发展与治疗]
Rev Fr Gynecol Obstet. 1961 Dec;56:821-6.
2
A cohort study of cervical cancer screening in British Columbia.不列颠哥伦比亚省宫颈癌筛查队列研究。
Clin Invest Med. 1982;5(1):1-29.
3
Appropriateness of cervical cancer screening.宫颈癌筛查的适宜性。
Gynecol Oncol. 1981 Oct;12(2 Pt 2):S168-87. doi: 10.1016/0090-8258(81)90072-x.
4
Estimated cervical cancer disease state incidence and transition rates.
J Natl Cancer Inst. 1981 Sep;67(3):571-6.
5
Simplified models of screening for chronic disease: estimation procedures from mass screening programmes.慢性病筛查简化模型:大规模筛查项目的估计程序
Biometrics. 1984 Mar;40(1):1-14.
6
Two-stage models for the analysis of cancer screening data.用于癌症筛查数据分析的两阶段模型。
Biometrics. 1987 Sep;43(3):657-69.
7
Epidemiology of uterine cervical cancer.子宫颈癌流行病学
J Chronic Dis. 1986;39(12):1051-65. doi: 10.1016/0021-9681(86)90139-6.
8
Organisation and results of the cervical cytology screening programme in British Columbia, 1955-85.1955 - 1985年不列颠哥伦比亚省宫颈细胞学筛查计划的组织与结果
Br Med J (Clin Res Ed). 1988 Apr 2;296(6627):975-8. doi: 10.1136/bmj.296.6627.975.
9
Natural history of cervical neoplasia: consistent results obtained by an identification technique.宫颈肿瘤的自然病史:通过一种识别技术获得的一致结果
Br J Cancer. 1989 Jul;60(1):132-41. doi: 10.1038/bjc.1989.236.
10
Cervical cancer screening.宫颈癌筛查
Br J Cancer. 1990 Aug;62(2):333-5. doi: 10.1038/bjc.1990.290.